Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1477 for:    abortion
Previous Study | Return to List | Next Study

Pharmacist Provision of Medication Abortion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04956731
Recruitment Status : Recruiting
First Posted : July 9, 2021
Last Update Posted : August 8, 2022
Sponsor:
Information provided by (Responsible Party):
Sarah Averbach, MD MAS, University of California, San Diego

Brief Summary:
This will be a pilot study among two pharmacists providing start to finish medication abortions to 10 patients utilizing a previously created toolkit. Following completion of the pilot, we will perform in-depth semi-structured interviews with the participating patients and pharmacists to understand their experiences with pharmacist provision of medication abortion. In addition, we will elicit feedback about ways to refine the toolkit to support the scale-up of pharmacist provision of medication abortion in the future.

Condition or disease Intervention/treatment Phase
Abortion in First Trimester Other: Pharmacist Provision of Medication Abortion Not Applicable

Detailed Description:

We will conduct a 'proof of concept' pilot study. Participating patients will be counseled by a trained pharmacist who will provide Mifepristone 200 mg and two doses of 800 mcg of Misoprostol. Patients will be instructed to take the 800 mcg of misoprostol buccally 24-48 hours after their Mifepristone. Patients whose estimated gestational age is between 64 and 70 days will be instructed to take the additional dose of 800 mcg of misoprostol 4 hours after the first dose. Patients who estimated gestational age is 63 days or less will be instructed to take the additional dose of 800 mcg of misoprostol if they do not experience at least moderate bleeding within the first 24 hours following their first misoprostol dose.

The patients will complete a brief 5-10 minute telehealth visit with a registered physician Mifepristone prescriber. The standard Mifepristone consent form will be signed at this time and the patient will then be instructed to take the Mifepristone orally.

Participants will be contacted one week after receiving treatment by the providing pharmacist. If the participant history suggests concern for a continuing pregnancy, ectopic pregnancy or worrisome bleeding, they will be scheduled for in person evaluation. If the participant does not indicate any concern, they will be instructed to use the high sensitivity urine pregnancy test four weeks after taking their misoprostol. If the participant's first high sensitivity urine pregnancy test is positive but they have no symptoms concerning for ongoing pregnancy, they will be instructed to perform a second, high sensitivity urine pregnancy test in one week. If the second, high sensitivity urine pregnancy test is also positive, the patient will be evaluated in person.

We will continue our study by performing in-depth semi-structured interviews with the participating patients and pharmacists to understand their experiences and elicit feedback about ways to refine the toolkit. We will follow a prepared interview guide.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Pharmacist Provision of Medication Abortion Pilot
Actual Study Start Date : January 12, 2022
Actual Primary Completion Date : July 1, 2022
Estimated Study Completion Date : September 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Medicines

Arm Intervention/treatment
Experimental: Pharmacist provision of medication abortion
This is a single arm study with 10 participants undergoing start to finish medication abortion provided by a pharmacist.
Other: Pharmacist Provision of Medication Abortion
Pharmacists providing start to finish medication abortions




Primary Outcome Measures :
  1. Completion of Medication Abortion [ Time Frame: 6 weeks ]
    Negative Pregnancy Test


Secondary Outcome Measures :
  1. Patient Satisfaction [ Time Frame: 2 weeks following completion of medication abortion ]
    qualitative analysis of post abortion in depth interviews

  2. Pharmacist Experience [ Time Frame: 2 weeks following completion of all 10 medication abortion visits ]
    qualitative analysis of post pilot in depth interviews

  3. Toolkit changes [ Time Frame: 2 weeks following completion of all 10 medication abortion visits ]
    per recommendation by participating pharmacists at post pilot in depth interviews



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18 or older
  • Pregnancy must be confirmed by either patient report of a positive urine pregnancy test, serum pregnancy test or ultrasound
  • Patient's last menstrual period (LMP) must be less than 70 days before the anticipated date of mifepristone administration
  • Patient must be certain of their LMP within 7 days and have regular menses
  • Patient has no symptoms or risk factors for ectopic pregnancy including bleeding or spotting in the week before their visit, prior ectopic pregnancy, significant pelvic pain the last week, prior permanent contraception or tubal surgery, current intrauterine device (IUD) in place or IUD in place at time of conception.

Exclusion Criteria:

  • Any contraindications to medication abortion, as reported on their medical history. These contraindicated include:

    1. Hemorrhagic bleeding disorder
    2. Current anticoagulation therapy
    3. Chronic adrenal failure
    4. Long-term systemic corticosteroid therapy
    5. Inherited porphyria

    d) Allergy to misoprostol or mifepristone

  • Any patient with complex medical conditions will also be excluded from this initial pilot. These medical conditions include:

    1. Poorly controlled hypertension as defined a history of systolic blood pressure >160 or diastolic blood pressure >110 or patients requiring two or more antihypertensive medication to control their blood pressure. This will be exclusion criteria for the study but it not a standard exclusion criteria for medication abortion
    2. Poorly controlled diabetes as defined by a known history of Type 1 or Type 2 diabetes with history of finger stick blood sugar >200 or HbA1c>10 in the last 6 months. This will be exclusion criteria for the study but it not a standard exclusion criteria for medication abortion
    3. Hepatic or renal failure
    4. History of solid organ transplant
    5. 4 or more cesarean sections
    6. Allergy to NSAIDs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04956731


Contacts
Layout table for location contacts
Contact: Selina Sandoval, MD 9162084861 smsandoval@ucsd.edu

Locations
Layout table for location information
United States, California
University of California, San Diego Recruiting
La Jolla, California, United States, 92103
Contact: Selina Sandoval    916-208-4861    smsandoval@ucsd.edu   
Sponsors and Collaborators
University of California, San Diego
Layout table for additonal information
Responsible Party: Sarah Averbach, MD MAS, Associate Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT04956731    
Other Study ID Numbers: 210175
First Posted: July 9, 2021    Key Record Dates
Last Update Posted: August 8, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sarah Averbach, MD MAS, University of California, San Diego:
medication abortion, no-test medication abortion, pharmacist